Oruka Therapeutics, Inc. ORKA
99.16 USD -0.39 (-0.40%)
Nov 4, 2026, 12:30 PM EST
96.34 Day range 102.59
26.38 52-week range 113.08
- YTD
- +227.14%
- 1 year
- +261.48%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 156.17 +57.5% upside
Now 99.16
- Target (low)
- 117.00
- Target (mean)
- 156.17
- Target (high)
- 200.00
Ratings (0m) 13 13 buy · 0 hold · 0 sell
- Strong buy2
- Buy11
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 13
- 1 month ago 13
- 2 months ago 13
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.61832 | -0.79 – -0.41 | -0.55 | -12.4% | 0 | 0.0% | 9 |
| Next quarter | -0.6627 | -0.86 – -0.40 | -0.45 | -47.3% | 0 | 0.0% | 9 |
| Current year | -2.37 | -2.90 – -1.83 | -1.85 | -27.9% | 0 | 0.0% | 9 |
| Next year | -2.86 | -4.09 – -2.19 | -2.37 | -21.0% | 0 | 0.0% | 9 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 27, 2026 | Guggenheim | Reiterated | Buy | Buy |
| Oct 27, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Oct 19, 2026 | BTIG | Reiterated | Buy | Buy |
| Sep 24, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Sep 24, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 3, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 11, 2026 | Guggenheim | Reiterated | Buy | Buy |
| Aug 11, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Aug 11, 2026 | BTIG | Reiterated | Buy | Buy |
| Aug 3, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 13, 2026 | BTIG | Reiterated | Buy | Buy |
| Jul 1, 2026 | UBS | Maintained | Buy | Buy |
| Jun 23, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 18, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 14, 2026 | BTIG | Reiterated | Buy | Buy |
| Apr 29, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 28, 2026 | UBS | Maintained | Buy | Buy |
| Apr 28, 2026 | Barclays | Maintained | Overweight | Overweight |
| Apr 27, 2026 | BTIG | Maintained | Buy | Buy |
| Apr 15, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Apr 13, 2026 | Guggenheim | Reiterated | Buy | Buy |
| Apr 13, 2026 | BTIG | Maintained | Buy | Buy |
| Apr 13, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 9, 2026 | Guggenheim | Reiterated | Buy | Buy |
| Apr 7, 2026 | Barclays | Maintained | Overweight | Overweight |
| Apr 6, 2026 | UBS | Maintained | Buy | Buy |
| Apr 6, 2026 | Guggenheim | Maintained | Buy | Buy |
| Mar 16, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Mar 13, 2026 | Barclays | Maintained | Overweight | Overweight |
| Mar 13, 2026 | BTIG | Reiterated | Buy | Buy |